NCT06806488

Brief Summary

This is a purely retrospective and observational monocentric study

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 4, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

February 4, 2025

Status Verified

October 1, 2024

Enrollment Period

5 months

First QC Date

December 3, 2024

Last Update Submit

January 28, 2025

Conditions

Marginal Zone B Cell Lymphoma

Outcome Measures

Primary Outcomes (1)

  • clinical characteristics of Marginal zone lymphoma patients

    to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.

    through study completion, an average of 1 years

Secondary Outcomes (2)

  • effectiveness

    through study completion, an average of 1 years

  • safety

    through study completion, an average of 1 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

You may qualify if:

  • Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018.
  • Age ≥ 18 years at enrolment.
  • Written informed consent (if applicable)

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Bologna, 40138, Italy

RECRUITING

MeSH Terms

Conditions

Lymphoma, B-Cell, Marginal Zone

Condition Hierarchy (Ancestors)

Lymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Pier Luigi Zinzani, MD

    IRCCS Azienda Ospedaliero-Universitaria di Bologna

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier Luigi Zinzani, MD

CONTACT

+39 0512143680pierluigi.zinzani@unibo.it

Alessandro Broccoli, MD

CONTACT

+39 0512143680Alessandro.broccoli@studio.unibo.it

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2024

First Posted

February 4, 2025

Study Start

May 1, 2025

Primary Completion

October 1, 2025

Study Completion

October 1, 2025

Last Updated

February 4, 2025

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations

IT(1)